Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PGNY 
Progyny Inc (PGNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PGNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $27.75
1 Year Target Price $27.75
| 4 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.84% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio 38.22 | 1Y Target Price 27.75 |
Price to earnings Ratio 38.22 | 1Y Target Price 27.75 | ||
Volume (30-day avg) 10 | Beta 1.32 | 52 Weeks Range 13.39 - 26.76 | Updated Date 08/15/2025 |
52 Weeks Range 13.39 - 26.76 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 0.16 | Actual 0.48 |
Profitability
Profit Margin 4.28% | Operating Margin (TTM) 7.32% |
Management Effectiveness
Return on Assets (TTM) 6.57% | Return on Equity (TTM) 10.94% |
Valuation
Trailing PE 38.22 | Forward PE 14.45 | Enterprise Value 1659316322 | Price to Sales(TTM) 1.56 |
Enterprise Value 1659316322 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 1.34 | Enterprise Value to EBITDA 20.54 | Shares Outstanding 85982400 | Shares Floating 79617991 |
Shares Outstanding 85982400 | Shares Floating 79617991 | ||
Percent Insiders 7.6 | Percent Institutions 97.53 |
Upturn AI SWOT
Progyny Inc
Company Overview
History and Background
Progyny Inc. was founded in 2008. It has evolved from a fertility benefits management company to a comprehensive fertility and family building benefits provider, focusing on improving outcomes and reducing costs.
Core Business Areas
- Fertility Benefits Management: Progyny provides fertility benefits management services, including access to a network of fertility specialists, treatment financing, and pharmacy benefits.
- Family Building Benefits: Expands offerings to include surrogacy, adoption, and other family-building services.
Leadership and Structure
The leadership team includes Pete Alcorn as CEO. Progyny operates with a traditional corporate structure with functional departments like sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Progyny Fertility Benefit: A comprehensive fertility benefit solution that includes access to a network of fertility specialists (the Progyny network), treatment financing through Progyny Rx (pharmacy benefits) and Progyny PQC (preconception and quality care). Progyny reports that its members have higher success rates and lower costs compared to traditional fertility benefits. Competitors include WINFertility, Carrot Fertility and Kindbody.
- Progyny Rx: A pharmacy benefit management program that specializes in fertility medications, offering competitive pricing and support services for patients undergoing fertility treatments. Competitors include specialty pharmacies such as MDR Pharmaceutical Care.
Market Dynamics
Industry Overview
The fertility benefits market is growing rapidly due to increasing infertility rates, greater awareness of fertility treatments, and employer demand for comprehensive benefits packages. The fertility market is very fragmented.
Positioning
Progyny positions itself as a premium provider of fertility benefits, differentiating itself through its network of high-quality fertility specialists, its integrated treatment financing model, and its focus on outcomes. They are positioned as a leader in outcomes and cost reduction.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars, reflecting the large number of employers and individuals seeking fertility benefits. Progyny is capturing an increasing share of this market by being a leader.
Upturn SWOT Analysis
Strengths
- Strong network of fertility specialists
- Integrated treatment financing model
- Focus on outcomes and cost reduction
- Strong relationships with employers
- Proprietary data and analytics capabilities
Weaknesses
- Premium pricing may limit market reach
- Reliance on employer-sponsored benefits
- Highly competitive market
- Dependence on the success of its network providers
Opportunities
- Expanding into new markets and geographies
- Developing new products and services
- Forming partnerships with healthcare providers
- Increasing awareness of fertility benefits
- Growing demand for family building benefits
Threats
- Increased competition from other fertility benefits providers
- Changes in healthcare regulations
- Economic downturn affecting employer benefits spending
- Technological advancements disrupting the fertility industry
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- WINF
- CRTO
- Kindbody
Competitive Landscape
Progyny's advantages include its strong network, integrated financing model, and focus on outcomes. Disadvantages include its premium pricing and reliance on employer-sponsored benefits.
Growth Trajectory and Initiatives
Historical Growth: Progyny has experienced rapid growth in recent years due to increasing demand for fertility benefits and its strong competitive position.
Future Projections: Analyst estimates suggest continued growth for Progyny in the coming years, driven by expanding market share and increasing awareness of fertility benefits. (Data for projections would be here in structured array format)
Recent Initiatives: Progyny has recently launched new products and services, such as surrogacy and adoption benefits, and expanded its network of providers.
Summary
Progyny is a strong company in the growing fertility benefits market, boasting a large market share and quality fertility outcomes. Key strengths are in its comprehensive solutions for employees. There is potential for increasing competition and economic downturns could impact employer spending on benefits. Overall the company appears to be financially strong based on its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Progyny Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-10-25 | CEO & Director Mr. Peter Anevski CPA | ||
Sector Healthcare | Industry Healthcare Plans | Full time employees 675 | Website https://www.progyny.com |
Full time employees 675 | Website https://www.progyny.com | ||
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.